News Immunomedics wows ESMO with breast cancer data reveal Immunomedics has revealed the trial data that convinced Gilead to stage a
Views & Analysis ESMO 2019 roundup The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.
News ESMO 2019 – new data could unlock bigger market for PARP inh... AstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as first-l
News ESMO 2019 - Amgen’s KRAS drug finds colorectal cancer a chal... Amgen’s KRAS inhibitor AMG 510 has shown little effect in colorectal cancer patients, according to new data reported at the
Views & Analysis Merck KGaA's bold new approach to cancer immunotherapy Germany’s Merck KGaA is hoping to stand out from the crowd with a bold new approach to cancer immunotherapy.
News Lilly bags FDA okay for Wegovy pill rival orforglipron Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
